Recombinant netrin-1 treatment reduced the growth rate of B-ALL cells in a dose-dependent manner, and the most effective concentration was 100 ng/ml for REH cells and 50 ng/ml for SUP-B15 cells. Here, NTN1 is linked to acute lymphoblastic leukemia.